Puglisi Fabio, Fontanella Caterina, Amoroso Vito, Bianchi Giulia Valeria, Bisagni Giancarlo, Falci Cristina, Fontana Andrea, Generali Daniele, Gianni Lorenzo, Grassadonia Antonio, Moscetti Luca, Portarena Ilaria, Rossi Emanuela, Marchetti Paolo
Department of Medical and Biological Science, University of Udine, Udine, Italy; Department of Oncology, University Hospital of Udine, Udine, Italy.
Department of Medical and Biological Science, University of Udine, Udine, Italy; Department of Oncology, University Hospital of Udine, Udine, Italy.
Crit Rev Oncol Hematol. 2016 Feb;98:211-21. doi: 10.1016/j.critrevonc.2015.10.016. Epub 2015 Oct 31.
The introduction of trastuzumab into routine clinical practice has had a dramatic effect on the outlook for patients with HER2-positive breast cancer. Nevertheless, answers to some long unresolved questions about the optimal use of trastuzumab (such as its role in small tumors or low-risk disease, cardiac safety in the elderly, and treatment duration) have emerged only relatively recently. Moreover, with the availability of new highly effective HER2-directed therapies, including pertuzumab and trastuzumab-emtansine (T-DM1), the treatment algorithm for HER2-positive breast cancer continues to evolve. This review provides a summary of the latest evidence providing insight into the management of early and advanced HER2-positive breast cancer and delineates future perspectives of study and treatment for these patients.
曲妥珠单抗引入常规临床实践对HER2阳性乳腺癌患者的预后产生了巨大影响。然而，一些关于曲妥珠单抗最佳使用的长期未解决问题（如在小肿瘤或低风险疾病中的作用、老年人的心脏安全性以及治疗持续时间）直到最近才出现相对明确的答案。此外，随着新型高效HER2靶向治疗药物（包括帕妥珠单抗和曲妥珠单抗-恩美曲妥珠单抗（T-DM1））的出现，HER2阳性乳腺癌的治疗方案仍在不断演变。本综述总结了最新证据，为早期和晚期HER2阳性乳腺癌的管理提供了见解，并阐述了这些患者未来的研究和治疗前景。
